Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Grint, Jennifer Doudna, Emmanuelle Charpentier

Premium

Regulus Therapeutics has appointed Paul Grint as its chief medical officer.

Grint joins the company from Cerexa, a subsidiary of Forest Laboratories, where he served as president and was responsible for the company's anti-infective product pipeline. Before that, he was senior vice president of research at Forest Research Institute.


Johnson & Johnson has announced that University of California, Berkeley's Jennifer Doudna and Hannover Medical School's Emmanuelle Charpentier have been named the winners of this year's Dr. Paul Janssen Award for Biomedical Research.

Doudna and Charpentier received the award for their groundbreaking research into CRISPR-Cas9, a bacterial immunity mechanism in which a short strand of RNA guides a nuclease to a specific area of DNA where it triggers double-strand breaks. The technology has since been refined and adopted by researchers for gene-editing applications.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more